Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shehara Mendis

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Oncotarget|November 17, 2018
Clinical application of cfDNA: moving in the right direction, but still a long way to goShehara Mendis, Jonathan M Loree
Clinical Colorectal Cancer|December 28, 2021
Biomarkers in Locally Advanced Rectal Cancer: A ReviewShehara Mendis, Yat Hang To, Jeanne Tie
Frontiers in Surgery|March 14, 2022
Surgical Techniques for Abdominoperineal Resection for Rectal Cancer: One Size Does Not Fit AllSimon Wilkins, Raymond Yap, Shehara Mendis, et al.
ANZ Journal of Surgery|July 26, 2023
Registry randomized controlled trials: the future of surgical trials?Yasser Arafat, Matthew Y Wei, Bill Karanatsios, et al.
Asia-Pacific Journal of Clinical Oncology|November 23, 2021
Treatment and outcomes of unresectable and metastatic pancreatic cancer treated in public and private Australian hospitalsYat Hang To, Julia Shapiro, Rachel Wong, et al.
Journal of Gastroenterology and Hepatology|January 23, 2026
Impact of BRAF Gene Mutation in Nonmetastatic Colorectal Cancer on Disease Progression and Survival OutcomesCaroline Lum, Harrison Boka, Mohammad Asghari-Jafarabadi, et al.
The Oncologist|September 22, 2020
Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic MalignanciesShehara Mendis, Seerat Anand, Joanna M Karasinska, et al.
JNCI Cancer Spectrum|June 14, 2022
Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal CancerShehara Mendis, Wei Hong, Sumitra Ananda, et al.
Clinical Colorectal Cancer|May 24, 2025
Exploring Real-World Outcomes of First Line EGFR Inhibitor Use, Cetuximab Versus Panitumumab, in Patients with Left-Sided, RAS Wild-Type, Metastatic Colorectal CancerJane McKenzie, Vanessa Wong, Shehara Mendis, et al.
Asia-Pacific Journal of Clinical Oncology|February 15, 2019
Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survivalShehara Mendis, Sophie Beck, Belinda Lee, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Oncotarget|November 17, 2018
Clinical application of cfDNA: moving in the right direction, but still a long way to goShehara Mendis, Jonathan M Loree
Clinical Colorectal Cancer|December 28, 2021
Biomarkers in Locally Advanced Rectal Cancer: A ReviewShehara Mendis, Yat Hang To, Jeanne Tie
Frontiers in Surgery|March 14, 2022
Surgical Techniques for Abdominoperineal Resection for Rectal Cancer: One Size Does Not Fit AllSimon Wilkins, Raymond Yap, Shehara Mendis, et al.
ANZ Journal of Surgery|July 26, 2023
Registry randomized controlled trials: the future of surgical trials?Yasser Arafat, Matthew Y Wei, Bill Karanatsios, et al.
Asia-Pacific Journal of Clinical Oncology|November 23, 2021
Treatment and outcomes of unresectable and metastatic pancreatic cancer treated in public and private Australian hospitalsYat Hang To, Julia Shapiro, Rachel Wong, et al.
Journal of Gastroenterology and Hepatology|January 23, 2026
Impact of BRAF Gene Mutation in Nonmetastatic Colorectal Cancer on Disease Progression and Survival OutcomesCaroline Lum, Harrison Boka, Mohammad Asghari-Jafarabadi, et al.
The Oncologist|September 22, 2020
Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic MalignanciesShehara Mendis, Seerat Anand, Joanna M Karasinska, et al.
JNCI Cancer Spectrum|June 14, 2022
Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal CancerShehara Mendis, Wei Hong, Sumitra Ananda, et al.
Clinical Colorectal Cancer|May 24, 2025
Exploring Real-World Outcomes of First Line EGFR Inhibitor Use, Cetuximab Versus Panitumumab, in Patients with Left-Sided, RAS Wild-Type, Metastatic Colorectal CancerJane McKenzie, Vanessa Wong, Shehara Mendis, et al.
Asia-Pacific Journal of Clinical Oncology|February 15, 2019
Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survivalShehara Mendis, Sophie Beck, Belinda Lee, et al.
Pageof 3